Adjuvant Therapy for Cutaneous Melanoma

Darryl Schuitevoerder; Charles C Vining; Jennifer Tseng

doi:10.1016/j.soc.2020.02.009

Adjuvant Therapy for Cutaneous Melanoma

Surg Oncol Clin N Am. 2020 Jul;29(3):455-465. doi: 10.1016/j.soc.2020.02.009.

Authors

Darryl Schuitevoerder¹, Charles C Vining¹, Jennifer Tseng²

Affiliations

¹ Department of Surgery, University of Chicago, 5841 South Maryland Avenue # MC5094, Chicago, IL 60637, USA.
² Department of Surgery, University of Chicago, 5841 South Maryland Avenue # MC5094, Chicago, IL 60637, USA. Electronic address: jtseng@surgery.bsd.uchicago.edu.

PMID: 32482320
DOI: 10.1016/j.soc.2020.02.009

Abstract

This article presents the current data supporting adjuvant therapy for patients with cutaneous melanoma. With the recent development of novel immunotherapy agents as well as targeted therapy, there are strong data to support the use of these therapies in patients at high risk of developing recurrent or metastatic disease.

Keywords: Adjuvant therapy; BRAF; Immunotherapy; MEK; Melanoma; Targeted therapy.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Chemotherapy, Adjuvant / methods*
Humans
Melanoma / drug therapy*
Melanoma / pathology
Molecular Targeted Therapy*
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / pathology
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology

Substances

Antineoplastic Agents